Document is current

Article History

Received: 13 December 2021

Accepted: 24 October 2022

First Online: 4 November 2022

Declarations

:

: This study was approved by the Niigata University Central Review Board of Clinical Research on 21 December 2020. All procedures will be performed in accordance with the ethical standards of the institutional and/or national research committee and with the 2013 Declaration of Helsinki and its later amendments or comparable ethical standards. All patients must provide written informed consent. This study is registered at the Japan Registry of Clinical Trials (jRCT), jRCTs031200319 (Registered 21 January 2021, ).

: Not applicable (this manuscript does not contain data from any individual person).

: Tetsuhiko Asao has received speakers bureau from AstraZeneca, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical.Satoshi Watanabe has received funding from AstraZeneca, speakers bureaus from AstaraZeneca, Nippon Kayaku, Ono Pharmaceutical, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, MSD, Taiho Pharmaceutical, Pfizer, Novaltis, Daiichi-Sankyo, Chugai Pharmaceuticals.Satoshi Morita has received research funding from Nippon Boehringer Ingelheim, honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, Astellas Pharma.Kunihiko Kobayashi has received funding from AstraZeneca, speakers bureaus from Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca.